Latest News

Latest News

A Regulatory Playbook for SaMD and Digital Health

A Regulatory Playbook for SaMD and Digital Health

Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

The first half of 2026 delivered one of the most consequential periods in recent biopharma history, reshaping competitive landscapes through record dealmaking, landmark regulatory approvals, and pivotal clinical breakthroughs. This biopharma H1 2026 review examines...

read more
CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

The CagriSema FDA review has become one of the most closely watched regulatory processes in metabolic medicine. Novo Nordisk filed a New Drug Application for its once-weekly obesity combination in December 2025, and a decision is widely expected in the final quarter...

read more
The Evidence Gap in Precision Prevention

The Evidence Gap in Precision Prevention

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a...

read more
Are Animal Models Limiting Progress in Product Development?

Are Animal Models Limiting Progress in Product Development?

While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...

read more
The Infrastructure Gap Behind the GLP-1 Boom

The Infrastructure Gap Behind the GLP-1 Boom

The rapid rise of GLP-1 medications has transformed healthcare delivery in ways few therapeutic categories have achieved in recent decades. Originally developed to help manage type 2 diabetes, GLP-1 receptor agonists such as semaglutide and tirzepatide have become...

read more
How Climate Change is Redrawing Europe’s Disease Landscape

How Climate Change is Redrawing Europe’s Disease Landscape

The impact of climate change is usually discussed in terms of heatwaves and floods. While less visible, its impact on infectious diseases is equally consequential for public health.  New data from the UK Health Security Agency (UKHSA) showing a surge in chikungunya...

read more
Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

The first half of 2026 delivered one of the most consequential periods in recent biopharma history, reshaping competitive landscapes through record dealmaking, landmark regulatory approvals, and pivotal clinical breakthroughs. This biopharma H1 2026 review examines...

read more
CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

The CagriSema FDA review has become one of the most closely watched regulatory processes in metabolic medicine. Novo Nordisk filed a New Drug Application for its once-weekly obesity combination in December 2025, and a decision is widely expected in the final quarter...

read more
The Evidence Gap in Precision Prevention

The Evidence Gap in Precision Prevention

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a...

read more
Are Animal Models Limiting Progress in Product Development?

Are Animal Models Limiting Progress in Product Development?

While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...

read more
The Infrastructure Gap Behind the GLP-1 Boom

The Infrastructure Gap Behind the GLP-1 Boom

The rapid rise of GLP-1 medications has transformed healthcare delivery in ways few therapeutic categories have achieved in recent decades. Originally developed to help manage type 2 diabetes, GLP-1 receptor agonists such as semaglutide and tirzepatide have become...

read more
How Climate Change is Redrawing Europe’s Disease Landscape

How Climate Change is Redrawing Europe’s Disease Landscape

The impact of climate change is usually discussed in terms of heatwaves and floods. While less visible, its impact on infectious diseases is equally consequential for public health.  New data from the UK Health Security Agency (UKHSA) showing a surge in chikungunya...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 13 July 2026

Weekly News Roundup | 13 July 2026

Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...

read more
Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...

read more
Clinical Trials Roundup | 10 July 2026

Clinical Trials Roundup | 10 July 2026

Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...

read more
FDA Drug Approval Decisions to Watch: July and August 2026

FDA Drug Approval Decisions to Watch: July and August 2026

The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...

read more
Atacicept FDA Approval: Trutakna Cleared for IgAN

Atacicept FDA Approval: Trutakna Cleared for IgAN

The atacicept FDA approval that the nephrology community had been anticipating since January arrived on schedule on 7 July 2026, when the US Food and Drug Administration granted accelerated approval to Vera Therapeutics' atacicept-vymj, to be marketed as Trutakna, for...

read more
AI Trust in Healthcare Starts with the People in the Room

AI Trust in Healthcare Starts with the People in the Room

Healthcare is on an accelerated path to digitisation, creating real opportunity to reduce administrative burden, improve risk detection, support prioritisation, and help people access the right care sooner. But without deliberate design, these same systems risk...

read more
The Regulatory Window for AI in Pharmacovigilance Is Open

The Regulatory Window for AI in Pharmacovigilance Is Open

In more than two decades of working with global CROs, pharmaceutical companies, and biotech organizations, I have watched pharmacovigilance teams absorb wave after wave of increasing complexity. More products on the market. More data sources to monitor. More...

read more

Further News

AI as a Research Partner for the Overstretched Life Sciences

Generative AI can lift the administrative weight of literature reviews and manuscript drafting, but only when it stays grounded in evidence and firmly under human control. The problem we know too well Every clinician who also publishes lives with a quiet collision. On...

FDA Clears First Glioma PET Imaging Drug After 2025 Rejection

The Food and Drug Administration has approved Pixclara, a glioma PET imaging drug from Telix Pharmaceuticals. Telix announced the decision in its approval announcement on 14 September 2026. The active ingredient is floretyrosine F 18, also written as 18F-FET. Telix...

Medical AI Is Getting Better. Why Is Diagnosis Getting Harder?

A radiologic study today rarely arrives alone. It comes wrapped in automated detection flags, quantitative lesion scores, an AI-drafted report, historical imaging, EHR clinical notes, and subspecialty consult requests. What it does not come wrapped in is medical AI...

Stellaromics Expands Pyxa Adoption Across the U.S. and Europe

Stellaromics Expands Pyxa® Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and Europe Icahn School of Medicine at Mount Sinai, CNAG, Karolinska Institutet, and Stanford University will apply 3D spatial multi-omics across...

Freeze-Dried Does Not Mean Pathogen-Free

Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...

Why AI Governance in Life Sciences Can’t Wait for Regulatory Clarity

The regulatory picture for AI governance in life sciences just got more confusing, not less. In June 2026, the European Union's Digital Omnibus package pushed back the EU AI Act's compliance deadline for stand-alone high-risk AI systems from August 2026 to December...

Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Two B7-H3 ADC trials beat topotecan in relapsed small cell lung cancer at WCLC 2026, but both ran only in China and neither is a filing package.

    Collagen Bioinks: A New Standard for 3D-Printed Tissue Constructs

    Collagen bioinks have to satisfy two very different demands. They need to behave predictably during printing, and once the printing stops they must also provide an environment in which cells can organise and begin behaving like tissue. However, it’s typically the...

    Autoimmune Serology Redefined: Deep B-Cell Depletion and IgG Blockade

    In October 2025, the FDA approved an anti-CD20 monoclonal antibody for adults with active lupus nephritis receiving standard therapy. In the phase 3 REGENCY trial, 46.4% of patients receiving B-cell depletion plus standard therapy achieved a complete renal response at...

    Radial Immunodiffusion Protocol and Troubleshooting: Why RID Still Matters

    Abstract Radial immunodiffusion (RID) can look almost outdated beside ELISA, multiplex assays, and automated analytical platforms. Yet that apparent simplicity may be exactly why the method still deserves attention. RID offers a direct, visually interpretable way to...

    Weekly News Roundup | 14 September 2026

    Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...

    Cabozantinib Salt Form Wins FDA Approval Past Malate Patents

    The FDA approved a new cabozantinib salt form on 11 September 2026, eleven days after the Federal Circuit upheld Exelixis’s malate salt patents.

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.